Hepatitis Clinical Trials

Showing 1841-1860 of 2,113 trials

Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone

NCT01025297

This study is designed to evaluate the safety of biological active dose of a new experimental drug, IL-7, in combination with standard bi-therapy in patients with Hepatitis C chronic infection identified as non responders to the standard bi-therapy alone.

Hepatitis C

Cytheris SA18 participantsStarted Jul 2008

Bondy, France • Clichy, France • Le Kremlin-Bicêtre, France +5 more locations

TERMINATEDPhase 2

Safety and Efficacy Study of L-FMAU in Chronic HBV Patients of L-FMAU-201 Placebo Group

NCT00313261

The purpose of this study is to evaluate the safety and antiviral activity of clevudine 30 mg QD for treatment of longer period (24 weeks) in patients chronically infected with HBV.

Hepatitis B

Bukwang PharmaceuticalStarted Jun 2003

Guro-dong, Guro-ku, Seoul, South Korea • Yeongeon-dong, Jongno-Gu, Seoul, South Korea • Ilwon-dong, Kangnam-Gu, Seoul, South Korea +4 more locations

COMPLETEDPhase 1

VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir

NCT01253551

The purpose of this study is to confirm the absence of a clinically relevant interaction between telaprevir and raltegravir at steady-state.Telaprevir is being investigated for the treatment of chronic hepatitis C virus infection, and raltegravir is used to treat HIV infection.

Hepatitis C

Tibotec BVBA21 participantsStarted Dec 2010

Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone

Safety and Efficacy Study of L-FMAU in Chronic HBV Patients of L-FMAU-201 Placebo Group

VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir

Related Searches

Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin

TMC435-TiDP16-C116 - Relative Bioavailability and Food Effect Study

Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)

Response to Booster Doses of Hepatitis B Vaccine in Children and Adolescents

Behavioral Intervention for HIV and HCV-Uninfected Injection Drug Users

Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients

Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients

36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8

Anti-tuberculosis (TB) Drug Levels and Correlation With Drug Induced Hepatotoxicity

Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and Ribavirin

TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir.

Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls

Follow Up of Patients Chronic Hepatitis B (CHB) Treated With Sebivo Using the 13C Methacetin Breath Test

Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials

Effects of Metformin, Pegylated Interferon Alpha and Ribavirin for Chronic Hepatitis C With Insulin Resistance

Switching Study From Lamivudine to Clevudine in the Chronic Hepatitis B Patients

Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB Infection